腦震盪市場 - 基於流行病學的當前市場價值(2021年)與預測(到2030年)，競爭新藥的價格策略，交易價值評估，r-NPV，開發平台藥物的分析(2022年前半期)

本報告提供全球腦震盪市場相關調查，提供市場概要，以及2030年前的預測，開發平台趨勢，競爭策略等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 腦震盪的概要與流行病學研究

第4章 腦震盪的目前市場價值與預測:2021年∼2030年

第5章 開發平台的洞察和基準概要

第6章 腦震盪的競爭領域的交易活動

第7章 腦震盪開發平台藥物的比較專利分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

第10章 市場動態

第11章 競爭企業的新藥的價格策略

GervanoRA's pipeline analysis and opportunity assessment report, "Concussion - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022" analysed and assessed Concussion pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Concussion drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Concussion area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Concussion drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Concussion historical and forecasted epidemiology based market trends Worldwide, the United States, EU8 (Poland, Spain, Switzerland, Sweden, Italy, Germany, Austria, France), United Kingdom and China. A detailed analytics on the Current Concussion Market (2021) and the Forecasted Concussion Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast

• Epidemiology Based Market Estimations - Current Market Value and Market Forecast

• Plotting of the Anticipated Market Share for the New Entrants

• Pricing Strategies of New Entrants Supported Through KOL Insights

• Risk-Adjusted Net Present Value (RNPV) Analysis

• Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type

• Unmet Needs and Opportunities

• Comparative Patent Analytics of Concussion Pipeline Drugs

• Competitive Opportunity Assessments of the Active Players in the Concussion Therapeutic Space by Partnering, Licensing and Funding Opportunities

• Deals Activities of Concussion Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: CONCUSSION OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: CONCUSSION CURRENT MARKET VALUE AND FORECAST 2021 - 2030

CHAPTER 5: COMPARATIVE PIPELINE INSIGHTS AND BENCHMARKING SNAPSHOTS

CHAPTER 6: DEALS ACTIVITIES OF CONCUSSION COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF CONCUSSION PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

CHAPTER 10: MARKET DYNAMICS

CHAPTER 11: COMPETITOR NEW DRUGS PRICING STRATEGIES

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

• TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
• TABLE 02: WORLDWIDE EPIDEMIOLOGY INSIGHTS OF CONCUSSION
• TABLE 03: GLOBAL CONCUSSION EPIDEMIOLOGY (2020), FORECAST (2021-2030)
• TABLE 04: US CONCUSSION EPIDEMIOLOGY (2020), FORECAST (2021-2030)
• TABLE 05: UK CONCUSSION EPIDEMIOLOGY (2020), FORECAST (2021-2030)
• TABLE 06: LIST OF NEW ENTRANTS CONSIDERED FOR MARKET ESTIMATIONS
• TABLE 07: CONCUSSION GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
• TABLE 08: CONCUSSION US CURRENT MARKET (2020), FORECAST (2021-2030)
• TABLE 09: COMPARISON OF CONCUSSION MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
• TABLE 10: PIPELINE ASSETS IN CONCUSSION DRUG PIPELINE
• TABLE 11: SPECIAL REGULATORY ALLOWANCES GRANTED FOR CONCUSSION PIPELINE DRUGS
• TABLE 12: CONCUSSION PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
• TABLE 13: CONCUSSION PIPELINE ANALYTICS BY DRUG CLASS
• TABLE 14: CONCUSSION PIPELINE ANALYTICS BY MECHANISM OF ACTION
• TABLE 15: CONCUSSION PIPELINE ANALYTICS BY MOLECULE TYPE
• TABLE 16: MAJOR MERGERS AND ACQUISITIONS IN CONCUSSION THERAPEUTIC AREA
• TABLE 17: MAJOR COLLABORATION AGREEMENTS IN CONCUSSION THERAPEUTIC AREA
• TABLE 18: MAJOR LICENSING AGREEMENTS IN CONCUSSION THERAPEUTIC AREA
• TABLE 19: MAJOR FINANCING AGREEMENTS IN CONCUSSION THERAPEUTIC AREA
• TABLE 20: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN CONCUSSION THERAPEUTIC AREA
• TABLE 21: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
• TABLE 22: ESTIMATED R&D INVESTMENTS OF NEW ENTRANTS

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

• FIGURE 01: CONCUSSION FORECASTED PREVALENCE & INCIDENCE OF US, EUROPE AND CHINA, 2020 V/S 2030
• FIGURE 02: GLOBAL CONCUSSION POPULATION (2020) FORECAST (2021-2030)
• FIGURE 03: US CONCUSSION POPULATION (2020) FORECAST (2021-2030)
• FIGURE 04: GLOBAL CONCUSSION MARKET CURRENT (2020) AND FORECAST (2021-2030)
• FIGURE 05: US CURRENT (2020) CONCUSSION MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
• FIGURE 06: YEAR BY YEAR COMPARISON OF CONCUSSION MARKET VALUES GLOBAL VS USA (2020 - 2030) (M$)
• FIGURE 07: CONCUSSION PIPELINE DRUGS ANALYTICS
• FIGURE 08: CONCUSSION PIPELINE DRUGS ANALYTICS BY HSD
• FIGURE 09: CONCUSSION PIPELINE ANALYTICS BY ROA
• FIGURE 10: CONCUSSION PIPELINE ANALYTICS BY DRUG CLASS
• FIGURE 11: CONCUSSION PIPELINE ANALYTICS BY DRUG CLASS VERSUS HSD
• FIGURE 12: CONCUSSION PIPELINE ANALYTICS BY MECHANISM OF ACTION
• FIGURE 13: CONCUSSION PIPELINE ANALYTICS BY MOLECULE TYPE
• FIGURE 14: CONCUSSION PIPELINE ANALYTICS BY COMPANY TYPE
• FIGURE 15: CONCUSSION DEALS ANALYTICS BY DEAL TYPE